HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Senate Wants PFAS Banned From Cosmetics. Should FDA Have A Say?

Executive Summary

Per- and polyfluoroalkyl substances are unpopular, sure. But there are thousands of PFAS with dissimilar safety profiles that merit US FDA review ahead of a blanket ban in cosmetic products, industry says.

You may also be interested in...



Ulta Ups FY 2022 Sales Projections; US House Targeting PFAS Research; Personal Care News In Brief

Ulta Beauty doubles its comparable sales growth projections for fiscal 2022 to between 6% and 8%, citing faster-than-expected makeup recovery. German company Henkel is recalling Alterna Bond Repair Leave-in Heat Protection Spray due to potential microbial contamination. More news in brief.

Industry Pushes For Revised PFAS Definition In California Bill Seeking Cosmetic Ban

The Personal Care Products Council and other industry groups suggest they will support AB 2771 if amendments are made to promote international harmonization, among other changes. Already they advocated successfully for the bill’s scope to be limited to intentionally added PFAS, not “the mere presence of trace levels of fluorine in the product.”

California Bill Could Target PFAS In Cosmetics, Intentionally Used Or Not

AB 2771, introduced in February, would ban the manufacture or sale of cosmetic products containing PFAS beginning on 1 January 2025, and it does not specify intentionally added PFAS versus those present as contaminants.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel